Arbutus Biopharma Corp Stock Number Of Shares Shorted
| ABUS Stock | USD 3.46 0.01 0.29% |
Arbutus Biopharma Corp fundamentals help investors to digest information that contributes to Arbutus Biopharma's financial success or failures. It also enables traders to predict the movement of Arbutus Stock. The fundamental analysis module provides a way to measure Arbutus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arbutus Biopharma stock.
Arbutus | Number Of Shares Shorted |
Arbutus Biopharma Corp Company Number Of Shares Shorted Analysis
Arbutus Biopharma's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Arbutus Biopharma Number Of Shares Shorted | 6.06 M |
Most of Arbutus Biopharma's fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arbutus Biopharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arbutus Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Arbutus Biopharma is extremely important. It helps to project a fair market value of Arbutus Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Arbutus Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arbutus Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arbutus Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Arbutus Biopharma Corp has 6.06 M of outstending shares currently sold short by investors. This is 89.29% higher than that of the Biotechnology sector and 18.8% higher than that of the Health Care industry. The number of shares shorted for all United States stocks is 28.7% lower than that of the firm.
Arbutus Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arbutus Biopharma's direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arbutus Biopharma could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics of similar companies.Arbutus Biopharma is currently under evaluation in number of shares shorted category among its peers.
Arbutus Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arbutus Biopharma from analyzing Arbutus Biopharma's financial statements. These drivers represent accounts that assess Arbutus Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arbutus Biopharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 158.7M | 269.2M | 413.3M | 351.7M | 414.9M | 435.6M | |
| Enterprise Value | 130.3M | 219.9M | 306.6M | 323.1M | 397.3M | 417.2M |
Arbutus Biopharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arbutus Biopharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arbutus Biopharma's managers, analysts, and investors.Environmental | Governance | Social |
Arbutus Fundamentals
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 529.29 M | ||||
| Shares Outstanding | 189.49 M | ||||
| Shares Owned By Insiders | 22.22 % | ||||
| Shares Owned By Institutions | 53.80 % | ||||
| Number Of Shares Shorted | 6.06 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 6.13 X | ||||
| Price To Sales | 97.25 X | ||||
| Revenue | 18.14 M | ||||
| Gross Profit | (45.39 M) | ||||
| EBITDA | (70.99 M) | ||||
| Net Income | (72.85 M) | ||||
| Cash And Equivalents | 150.2 M | ||||
| Cash Per Share | 1.00 X | ||||
| Total Debt | 8.72 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.29 X | ||||
| Book Value Per Share | 0.56 X | ||||
| Cash Flow From Operations | (85.94 M) | ||||
| Short Ratio | 6.34 X | ||||
| Earnings Per Share | (0.43) X | ||||
| Target Price | 7.28 | ||||
| Number Of Employees | 73 | ||||
| Beta | 1.92 | ||||
| Market Capitalization | 655.64 M | ||||
| Total Asset | 144.4 M | ||||
| Retained Earnings | (1.28 B) | ||||
| Working Capital | 109.54 M | ||||
| Current Asset | 183.88 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 144.4 M |
About Arbutus Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arbutus Biopharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arbutus Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arbutus Biopharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.